



[haematologica]
2004;89:985-990

Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation

MURRAY ADAMS
LIZA BRECKLER
PAUL STEVENS
JIM THOM
ROSS BAKER
ROBERT OOSTRYCK

A B S T R A C T

Background and Objectives. Immunoglobulin G (IgG) fractions from subjects with antiphospholipid syndrome (aPS) have previously been demonstrated to have inhibitory activity against tissue factor pathway inhibitor (TFPI). This may contribute to the development of a prothrombotic state by impaired regulation of the tissue factor (TF) pathway. This study investigated the effect that IgG fractions from aPS subjects containing anti-TFPI activity have on *in vitro* TF-induced thrombin generation.

Design and Methods. TFPI and anti-TFPI activities were determined in normal controls (n=29) and aPS subjects (n=57). TFPI activity was determined using an amidolytic assay based on the generation of factor Xa. Anti-TFPI activity was determined after incubating IgG isolated from a control or subject plasma with pooled normal plasma, using the TFPI activity assay. The influence of IgG fractions from controls (n=10) and subjects (n=23) on TF-induced *in vitro* thrombin generation was determined using a chromogenic assay of thrombin activity.

Results. TFPI activity in controls (1.13 ± 0.25 U/mL) was significantly lower than in subjects (1.30 ± 0.42 U/mL) ($p < 0.05$). Anti-TFPI activity was significantly higher in subjects than controls ($p = 0.0001$). TF-induced thrombin generation was positively associated with anti-TFPI activity ($p = 0.356$; $p > 0.05$), with increased levels of each demonstrated in 5 subjects.

Interpretations and Conclusions. Anti-TFPI activity was confirmed in 65% of aPS subjects. IgG fractions demonstrated a variable ability to interfere with TFPI function and TF-induced thrombin generation. Cross-reacting antiphospholipid antibodies and/or other entities may interfere with TFPI function, resulting in a net increase in thrombin generation and an increased thrombotic risk.

Key words: antiphospholipid syndrome, TFPI, thrombosis, anti-TFPI activity.

From the School of Biomedical Sciences, Curtin University of Technology, Perth, Australia (MA, LB, PS, RO); Department of Haematology, Royal Perth Hospital, Perth, Australia (JT, RB).

Correspondence: Murray Adams, School of Biomedical Sciences, Curtin University of Technology GPO Box U 1987, Perth WA 6845 Australia. E-mail: m.adams@curtin.edu.au

©2004, Ferrata Storti Foundation

The antiphospholipid syndrome (aPS) is a heterogeneous disorder characterized by circulating antiphospholipid antibodies (aPL), with venous or arterial thrombosis, recurrent miscarriages and thrombocytopenia.¹ APL target phospholipid bound proteins, including β -2-glycoprotein-I (β 2GPI) and prothrombin, with varying specificity.² It has been proposed that aPL contribute directly to the clinical manifestations of aPS,² though no single mechanism has been clearly identified. On the other hand, the heterogeneity of clinical manifestations of aPS probably reflects multiple contributing factors that lead to the development of hypercoagulability. These include, but are not limited to, interference with platelet function,^{3,4} inhibition of the protein C anticoagulant system^{5,6} and inhibition of fibrinolysis.⁷

Changes to the tissue factor (TF) pathway of coagulation have more recently been implicated in the development of hypercoagulability in aPS.⁸ Indeed, inhibitory activity (in IgG fractions) against tissue factor pathway inhibitor (TFPI)⁹ and autoantibodies (in plasma) to TFPI^{10,11} have been identified in aPS subjects. Whether these are actually the same entity remains to be elucidated, but it would seem feasible that anti-TFPI activity is due to the contribution of anti-TFPI antibodies and possibly other cross-reacting aPL. An impaired ability of TFPI to regulate the TF pathway, for example by an anti-TFPI antibody or another interfering factor, may contribute significantly to the development of a prothrombotic state. The aim of this study was, therefore, to investigate how *in vitro* TF-induced thrombin generation was affected by IgG fractions from aPS subjects containing anti-TFPI activity.

Design and Methods

Ethics

The study was approved by the Human Research Ethics Committee of Curtin University (*Approval Number: HR 238/2001*) and the Ethics Committee of Royal Perth Hospital (*Reference: EC 2002/013*).

Patients and controls

Venous blood was collected from 29 normal controls (M=18; F=11; mean age: 24.6±8.6 years) and 57 aPS subjects (M=28; F=29; mean age: 50.2±20.2 years). Subjects presented with a history of aPS-related clinical features or demonstrated aPS laboratory markers. Nine parts whole blood was collected into 1 part 0.109 mol/L tri-sodium citrate. Plasma was prepared by centrifugation at 1,800 g for 15 minutes at room temperature. The plasma was separated and centrifuged again to ensure that platelet-poor plasma was collected. Samples were aliquoted and stored at -70°C until required.

Pooled normal plasma was prepared from 20 normal male donors. Equal volumes of plasma from each donor were pooled, mixed, aliquoted and stored at -70°C until required. Pooled normal plasma was designated to contain 1 U/mL TFPI activity.

TFPI activity assay

TFPI activity was measured using an amidolytic assay based on a previously described method.¹² Prior to the assay, test or standard plasmas were heated at 56°C for 15 minutes, placed on melting ice for 2 minutes then centrifuged for 15 minutes at 1,800 g. Diluted test or standard plasma (25 µL) was incubated with 100 µL of a reaction mixture, which contained equal amounts of recombinant TF (Innovin®, Dade Behring, Marburg, Germany) (diluted 1/40 in TFPI assay buffer containing 0.15 mol/L NaCl, 0.05 mol/L Tris, 0.01 mol/L trisodium citrate, 0.1% normal serum albumin and 0.02% polybrene, pH 8.0), 0.03 U/mL FVII (Enzyme Research Laboratories, Southbend, USA), 0.025 U/mL FX (Sigma Chemical Company, St Louis, USA), and 0.05 mol/L CaCl₂, in U-bottomed microtiter plates (Australian Bioscience, Perth, Australia). After incubation for 20 minutes at 37°C, 50 µL of substrate mixture, containing 0.4 U/mL FX and 2.7 mmol/L synthetic peptide substrate (S-2222; Chromogenix, Milan, Italy), were added and incubated at 37°C for a further 30 minutes. The reaction was stopped by the addition of 50 µL of 50% acetic acid and the absorbance read at 405 nm using a Multiskan Acent microtiter plate spectrophotometer. The assay was standardized using pooled normal plasma from 20 healthy male donors.

IgG isolation

IgG fractions were isolated from plasma by affinity purification using a protein G column according to the manufacturer's instructions (Amersham Pharmacia Biotech, Uppsala, Sweden). Samples were diluted 1 in 5 in 0.02 mol/L phosphate-buffered saline (PBS) pH 7.4 and pushed slowly through the column using an attached syringe. After washing the column with 10 mL of 0.02 mol/L PBS pH 7.4, IgG was eluted with 5 mL of 0.1 mol/L glycine-HCl pH 2.8 and collected as 1 mL aliquots into 100 µL of 1.0 mol/L tris-HCl pH 9.0. The absorbance of each aliquot was measured at 280 nm and the two aliquots with the highest absorbance and 0.5 mL of the third highest aliquot were pooled. Buffer exchange was performed using PD 10 desalting columns (Amersham Pharmacia Biotech, Uppsala, Sweden), equilibrated with 15 mL of TFPI assay buffer pH 8.0 or 0.02 mol/L PBS pH 7.4. Isolated IgG (2.5 mL) was passed through the desalting column and eluted with 3.5 mL of the appropriate buffer. The concentration of IgG was determined by measuring the absorbance of the pooled aliquots with a 1 cm light path and an extinction coefficient of $E^{1\%, 1\text{cm}} = 13.6$, and stored at -70°C.

Preparation of pooled normal IgG

Following isolation (as described above) from 22 normal controls, IgG fractions were adjusted to a concentration of 500 µg/mL with PBS pH 7.4 and an equal volume of each fraction pooled, aliquoted and stored at -70°C until required.

Determination of anti-TFPI activity

IgG fractions (25 µg/mL) were mixed with pooled normal plasma for 30 minutes at 37°C. The IgG and pooled normal plasma mixtures were then re-assayed for TFPI activity. Anti-TFPI activity was designated as the difference between TFPI activity in the IgG-pooled normal plasma mixture and the control (buffer/pooled normal plasma; 1 U/mL).

Assay of thrombin generation

A chromogenic assay based on the method of Sheng et al.¹³ was used to determine the effect of IgG fractions from controls and aPS subjects on TF-induced *in vitro* thrombin generation. Plasma was initially defibrinated by heating at 53°C for 20 minutes, incubation on melting ice for 2 minutes and centrifugation at 3,000 g for 10 minutes. Thromboplastin (25 µL, diluted 1/10 in 0.9% NaCl) and 50 µL of defibrinated plasma (diluted 1/2 in 0.02 mol/L PBS pH 7.4 or 25 µg/mL IgG/antibody) were incubated for 10 minutes at 37°C. Chromozyme TF substrate (Roche Diagnostics, Sydney, Australia) was diluted in 0.9% NaCl to a concentration of 0.95 mmol/L and 50 µL added to each well. Following addition of 30




Figure 1. TFPI activity in normal controls and aPS subjects. TFPI activity was significantly higher in aPS subjects than in controls ($p < 0.05$) as measured by an amidolytic activity assay.




Figure 2. Anti-TFPI activity in controls and aPS subjects. Anti-TFPI activity was significantly higher in aPS subjects than in controls ($p = 0.0001$) as measured by mixing IgG (25 $\mu\text{g/mL}$) from controls or aPS subjects with pooled normal plasma and measuring by the TFPI amidolytic activity assay.

mmol/L CaCl_2 (50 μL), the absorbance was measured at 405 nm every two minutes until the peak absorbance was obtained. Each sample was measured for background absorbance by substituting TF with 25 μL of 0.9% NaCl. At each time point the absorbance of the background wells was subtracted from the absorbance of the corresponding test wells. This resulted in the final corrected absorbance for each sample assessed. Thrombin generation (%) was determined by dividing the absorbance at 1/2max of the test mixture by the absorbance at 1/2max of a blank (containing 0.9% NaCl instead of test or control IgG).

A sheep anti-rabbit TFPI antibody (a gift from Dr P. Tipping, Monash University, Australia) and pooled IgG from normal controls were used as controls.

Statistics

Results were analyzed using StatViewSE+Graphics for Macintosh (Abacus Concepts, Berkeley, USA). Results are expressed as mean \pm standard deviation (SD) for TFPI activity or median (inter-quartile range) for other data sets. Between group differences were assessed using Student's t-test for normally distributed data (TFPI activity) or the Wilcoxon signed rank test for non-parametric data. Correlations between sets of data was determined using Spearman's correlation co-efficient. p values < 0.05 were considered to be statistically significant.

Results

TFPI activity

TFPI activity (mean \pm SD) in controls (1.13 ± 0.25 U/mL) was significantly lower than in aPS subjects (1.30 ± 0.42

U/mL) ($p < 0.05$) (Figure 1). Two aPS subjects had TFPI activity below the lower 95% confidence interval (< 0.63 U/mL) of the normal range (0.57 and 0.53 U/mL, respectively). Seven aPS subjects had TFPI activity above the upper 95% confidence interval (> 1.63 U/mL) of the derived normal range.

Anti-TFPI activity

Anti-TFPI activity was detected in 3/29 (10%) controls (0.01, 0.02 and 0.02 U/mL) and in 37/57 (65%) aPS subjects [median = 0.03 (0.02 – 0.06 U/mL)] (Figure 2). Anti-TFPI activity was significantly greater in aPS subjects than in controls ($p = 0.0001$). There was no correlation between TFPI activity and anti-TFPI activity in either control or subject cohorts ($p > 0.05$).

TF-induced thrombin generation

The standard curve for the detection of *in vitro* TF-induced thrombin was sigmoidal in shape (Figure 3), as previously demonstrated.¹³ A sheep anti-rabbit TFPI antibody induced a concentration-dependent increase in thrombin generation (Figure 4). Pooled IgG from normal donors demonstrated no effect on thrombin generation (Figure 4). The effect on TF-induced thrombin generation by IgG fractions from 10 controls and 23 aPS subjects was variable [100.5% (97.0 – 102.0%) vs 98.0% (89.5 – 105.5%)] ($p > 0.05$) (Figure 5). The effect of IgG fractions from 23 of 57 aPS subjects tested on thrombin generation was positively correlated ($p = 0.356$) with anti-TFPI activity (Figure 6), but this was not statistically significant ($p = 0.09$). There was no correlation between the effect of IgG on *in vitro* TF-induced thrombin generation and TFPI activity in either control ($p > 0.05$) or subject cohorts ($p > 0.05$).




Figure 3. TF-induced thrombin generation assay: standard curve. Thrombin generation of pooled normal plasma as detected by a chromogenic substrate measured over time.




Figure 4. TF-induced thrombin generation assay: controls. Sheep anti-rabbit TFPI antibodies (crosses) inhibit TFPI and therefore induce a concentration-dependent increase in thrombin generation. Pooled normal IgG (circles) have no effect on thrombin generation.




Figure 5. Effect of IgG fractions from controls and aPS subjects on TF-induced thrombin generation. IgG from controls (crosses) have a narrow influence on thrombin generation. IgG from aPS subjects (circles) have a wide influence on thrombin generation.




Figure 6. Scatterplot of anti-TFPI activity vs TF-induced thrombin generation using IgG from aPS subjects ($p = 0.356$).

Discussion

Venous or arterial thrombosis is a frequent clinical manifestation of aPS, though causal mechanisms remain to be elucidated. It is probable that the development of a hypercoagulable state is a consequence of multiple significant abnormalities and/or imbalances of hemostatic mechanisms, including the TF pathway. TFPI activity levels were initially demonstrated to be higher in aPS subjects than in controls. Though variable levels of TFPI activity (and antigen) have been reported in aPS subjects¹⁴⁻¹⁷ recent experimental evidence supports up-regulation of the TF pathway as an important factor in the development of hypercoagulability in aPS.^{8,9,11,18} Indeed,

increased TFPI activity in the plasma of aPS subjects probably represents increased endothelial cell secretion of TFPI. This may be a protective mechanism in response to the direct influence of aPL, which have been demonstrated to induce an increase in TF-like activity in monocytes and endothelial cells.¹⁸⁻¹⁹

The presence of anti-TFPI activity was confirmed in the cohort of aPS subjects used in this study. Interestingly, anti-TFPI activity was demonstrated in a greater proportion of subjects compared to an earlier study (65% vs 15%).⁹ It is unclear why there is a large discrepancy between these results, as the methods to measure anti-TFPI activity were essentially the same. A relatively small sample size in each study, or the use of fresh pooled nor-

mal plasma instead of lyophilized reference plasma (not calibrated for TFPI) to detect anti-TFPI activity, may have contributed to the discrepant results.

The range of anti-TFPI activity in aPS subjects was 0.01 – 0.10 U/mL, reflecting variability in the strength of the interference. Three (10%) of 29 normal controls also demonstrated anti-TFPI activity, although levels (0.01 – 0.02 U/mL) were lower than those detected in the majority of aPS subjects. This was not an unexpected observation as laboratory markers of aPS, lupus anticoagulants (LA) and anticardiolipin antibodies (aCL), have been reported in the plasma of normal individuals.²⁰⁻²³ Anti-TFPI autoantibodies have also been reported in a small percentage of normal individuals.¹¹

The primary aim of this study was to investigate the influence of IgG fractions from aPS subjects on *in vitro* TF-induced thrombin generation. The assay, based on a previously published method,¹³ measures the effect of antibody, IgG or plasma in a chromogenic substrate assay of thrombin generation. It detects both LA and β 2GPI dependent aCL antibodies and probably has greater specificity for aPS than currently available diagnostic tests.¹³ It was hypothesized in the present study that IgG fractions obtained from the plasma of aPS subjects which contained anti-TFPI activity would increase *in vitro* TF-induced thrombin generation. Physiological concentrations of TFPI have been demonstrated to reduce the rate of thrombin generation,²⁴ thus it was predicted that inhibition of TFPI activity would increase the rate of thrombin generation.

It was initially demonstrated in control experiments that a sheep anti-rabbit TFPI antibody increased *in vitro* TF-induced thrombin generation in a concentration-dependent manner and that pooled normal IgG had no effect on thrombin generation in the same system. These controls confirmed that changes to thrombin generation were due to interference of TFPI activity by a component of the IgG fractions.

The effect of IgG fractions from normal controls on thrombin generation demonstrated a narrow inter-quartile range of 97–102%. This variation may be accounted for by the incidental presence of aPL in the IgG fractions of apparently healthy subjects²⁵ and might therefore influence thrombin generation. The effect of IgG fractions from aPS subjects, however, was more variable, with a wider inter-quartile range (89.5% – 105.5%) and low and high values of 49% and 131%, respectively, indicating a variety of influences from IgG fractions on TF-induced thrombin generation. In particular, increased thrombin generation may be due to interference with TFPI activity, for example by anti-TFPI antibodies and/or other cross-reacting aPL, reflecting increased hypercoagulability and thrombotic risk.

Anti-TFPI activity in aPS subjects was weakly corre-

lated with the effect of IgG fractions on TF-induced *in vitro* thrombin generation ($p = 0.356$). Interestingly, increased thrombin generation (above the 75% percentile of the normal cohort; 102%) and anti-TFPI activity were reported in 5 of the 23 aPS subjects tested. The presence of anti-TFPI activity in the plasma of these subjects could contribute significantly to an increased thrombotic risk. A larger cohort of subjects may demonstrate a significant positive correlation between anti-TFPI activity and the resulting influence of IgG fractions (or purified anti-TFPI autoantibodies from these subjects) on TF-induced *in vitro* thrombin generation.

Low TF-induced thrombin generation (below the 25th percentile of the normal cohort; 97%) was reported in 10 of the 23 subjects tested. This is probably due to the presence of LA, which paradoxically interfere with *in vitro* phospholipid-dependent coagulation tests [including the thrombin generation assay used in this study]¹³ by prolonging clotting times, thus reflecting decreased, rather than increased thrombin generation. Each of the 10 subjects tested was positive for LA. It is also interesting to note that the 5 IgG fractions that generated increased TF-induced thrombin generation were also positive for LA, indicating that the overall strength of anti-TFPI activity was greater than the influence of LA. The model used in this study therefore accounts for the overall capacity of anti-TFPI activity in IgG fractions, which potentially contain LA, aCL and other entities, to influence thrombin generation, rather than the influence of anti-TFPI antibodies alone.

This study has confirmed the presence of anti-TFPI activity in aPS subjects, demonstrating that IgG fractions generate variable influences on TF-induced thrombin generation and associated anti-TFPI activity with increased thrombin generation. Whether the anti-TFPI activity demonstrated in this *in vitro* system represents the presence of *in vivo* anti-TFPI autoantibodies, other aPL that interfere with TFPI activity such as anti- β 2GPI²⁶ or a combination of both, is yet to be determined. The overall contribution of these factors and others, such as the influence of aPL on TF expression or secretion, may be significant in altering the balance of the TF pathway and the development of the clinical manifestations associated with aPS.

MA is the author taking primary responsibility for this paper. MA, LB, PS, JT, RB and RO each contributed to the conception and design of the study, data analysis, interpretation of results, and preparation and review of the manuscript. LB and PS performed the experiments and collected the data. The authors reported no potential conflicts of interest.

The authors acknowledge the financial assistance of the School of Biomedical Sciences at Curtin University of Technology in conducting this study.

Manuscript received March 3, 2004. Accepted June 7, 2004.

References

1. Wilson W, Gharavi A, Koike T, Lockshin M, Branch W, Piette J, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum* 1999;42:1309-11.
2. Roubey RAS. Immunology of the antiphospholipid syndrome: antibodies, antigens and autoimmune response. *Thromb Haemost* 1999;82:656-61.
3. Martinuzzo ME, Maclof J, Carreras LO, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. *Thromb Haemost* 1993;70:667-71.
4. Shi W, Chong BH, Hogg PJ, Chesterman CN. Anticardiolipin antibodies block the inhibitor by β 2-glycoprotein I of the factor Xa generating activity of platelets. *Thromb Haemost* 1993;70:342-5.
5. Cariou R, Tobelem G, Bellucci S, Soria J, Sora C, Maclof J, et al. Effect of lupus anticoagulant on antithrombotic properties of endothelial cells – inhibition of thrombomodulin-dependent protein C activation. *Thromb Haemost* 1988;60:54-8.
6. Oosting JD, Derksen RHW, Bobbink IWG, Hackeng TM, Bouma BN et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism. *Blood* 1993;81:2618-25.
7. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. The fibrinolytic response to venous occlusion and the natural anticoagulant in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. *Br J Haematol* 1991;77:354-9.
8. Amengual O, Atsumi T, Munther A, Kahamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. *Thromb Haemost* 1998;79:276-81.
9. Adams MJ, Donohoe S, Mackie IJ, Machin SJ. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. *Br J Haematol* 2001;114:375-9.
10. Cakir B, Arnett FC, Roubey RAS. Autoantibodies to tissue factor pathway inhibitor (TFPI) are associated with arterial thrombosis/stroke. *J Autoimmun* 2000;15:OC25[abstract].
11. Forastiero RR, Martinuzzo ME, Broze GJ. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. *J Thromb Haemost* 2003;1:718-24.
12. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. *Blood Coagul Fibrinol* 1991;2:425-33.
13. Sheng Y, Hanly JG, Reddel SW, Kouts S, Guerin J, Koike T, et al. Detection of antiphospholipid antibodies: a single chromogenic substrate of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding β 2-glycoprotein I and prothrombin. *Clin Exp Immunol* 2001;12:4502-8.
14. Adams MJ, Dunstan RA, Oosttryck R. Interference by lupus anticoagulant in a functional assay for tissue factor pathway inhibitor. *Thromb Res* 1995;80:435-40.
15. Adams MJ, Oosttryck R. Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor. *Thromb Res* 1997;87:245-9.
16. Kiraz S, Ertenli L, Benekli M, Haznadaroglu IC, Calguneri M, Celik I, et al. Clinical significance of the hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. *Lupus* 1999;8:737-41.
17. Wakita Y, Wada H, Nakase T, Nakasaki T, Shimura M, Hiroyama K, et al. Aberrations of the tissue factor pathway in patients positive for lupus anticoagulant. *Clinical and Applied Thromb Haemost* 1999;5:10-5.
18. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. *J Immunol* 1994;153:1328-32.
19. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. *Am J Obstet Gynecol* 1993;168:206-10.
20. Lechner K, Pabinger-Fasching IP. Lupus anticoagulant and thrombosis. A study of 25 cases and review of the literature. *Haemostasis* 1985;15:252-62.
21. Triplett DA, Brandt JT, Maas RL. The laboratory heterogeneity of lupus anticoagulants. *Archiv Pathol Lab Med J* 1985;109:946-51.
22. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. *Ann Intern Med* 1990;112:682-98.
23. Lynch A, Marlar R, Murphy J, Davila G, Santo M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. *Ann Intern Med* 1994;120:470-5.
24. Veer CV, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin II and heparin cofactor II. *J Biol Chem* 1997;272:4367-77.
25. Greaves M. Antiphospholipid syndrome: state of the art with emphasis on laboratory evaluation. *Haemostasis* 2000;30 Suppl 2:16-25.
26. Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T. Antibodies to β 2GPI associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. *Thromb Haemost* 2000;84:653-6.